Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label umbrella study of SKB571 in advanced or metastatic pancreatic cancer
CTR20263347Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SKB571 in pancreatic cancer (PC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Aug 2026; status: active.
02
Drugs
SKB571
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20263347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263347.